Dr. Verghese is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
920 Germantown Pike
Suite 102
Plymouth Meeting, PA 19462Phone+1 610-277-8073Fax+1 610-277-8046
Summary
- My background is in academic research, teaching and administration. I founded Keystone Clinical Studies in 2003. I have conducted over 150 clinical trials as Principal Investigator, leading to the approval of 10 medications in Psychiatry and Neurology. We are nationally recognized as a premier site for clinical trials of disease modifying therapies in Alzheimer's disease. I am a Key Opinion Leader in the field, and help in the design of clinical trials with Pharma, CROs and advocacy groups like the Alzheimer's Association.
Education & Training
Drexel University College of Medicine/Hahnemann University HospitalResidency, Psychiatry, 1992 - 1995
Grant Medical CollegeClass of 1984
Certifications & Licensure
PA State Medical License 1991 - 2024- American Board of Psychiatry and Neurology Psychiatry
Awards, Honors, & Recognition
- Scientific Research Award NAMI, Montgomery County, PA, 2020
- Charles Ewing Memorial Presidential Award Eastern Pennsylvania Geriatrics Society, 2019
- Best Teacher Albert Einstein Residency Training Program, 2001
Clinical Trials
- Safety and Tolerability Study of Oral OPC-34712 as Maintenance Treatment in Adults With Schizophrenia Start of enrollment: 2011 Sep 01
- Open-label Safety Study in Adults With ADHD Start of enrollment: 2014 Jun 01
Publications & Presentations
PubMed
- 2 citationsA long-term, open-label study of valbenazine for tardive dyskinesia.Jean-Pierre Lindenmayer, Cherian Verghese, Stephen R. Marder, Joshua Burke, Roland Jimenez
CNS Spectrums. 2021-08-01 - 21 citationsA Phase 3, 1-Year, Open-Label Trial of Valbenazine in Adults With Tardive DyskinesiaStephen R. Marder, Carlos Singer, Jean-Pierre Lindenmayer, Caroline M. Tanner, Cynthia L. Comella
Journal of Clinical Psychopharmacology. 2019-11-01
Press Mentions
Philadelphia Alzheimer's Disease Patient Involved in Groundbreaking TrialApril 14th, 2022
Neuroendocrine Factors Influencing Polydipsia in Psychiatric Patients: An HypothesisJuly 22nd, 2020
Professional Memberships
- Member
Industry Relationships
- Principal Investigator, Lilly, Janssen, Eisai, ATRI, Cassava, AbbVie, Roche, Athira, Otsuka, Sage, Neurocrine, etcPrincipal Investigator, Key Opinion Leader, Advisory Board Member, Speakers Bureau,Disclosure: I serve as Principal Investigator for multiple Pharma, but do not hold any direct stock in any of these2003 - Present
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
